Teva Pharmaceutical Industries (TEVA) Operating Leases (2018 - 2025)
Historic Operating Leases for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Q4 2025 value amounting to $288.0 million.
- Teva Pharmaceutical Industries' Operating Leases fell 270.27% to $288.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $288.0 million, marking a year-over-year decrease of 270.27%. This contributed to the annual value of $288.0 million for FY2025, which is 270.27% down from last year.
- As of Q4 2025, Teva Pharmaceutical Industries' Operating Leases stood at $288.0 million, which was down 270.27% from $283.0 million recorded in Q3 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Operating Leases registered a high of $525.0 million during Q4 2021, and its lowest value of $281.0 million during Q2 2024.
- Its 5-year average for Operating Leases is $357.0 million, with a median of $341.5 million in 2023.
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Operating Leases surged by 729.93% in 2021, and later crashed by 2901.68% in 2024.
- Teva Pharmaceutical Industries' Operating Leases (Quarter) stood at $525.0 million in 2021, then fell by 15.81% to $442.0 million in 2022, then dropped by 5.66% to $417.0 million in 2023, then fell by 29.02% to $296.0 million in 2024, then decreased by 2.7% to $288.0 million in 2025.
- Its Operating Leases was $288.0 million in Q4 2025, compared to $283.0 million in Q3 2025 and $296.0 million in Q2 2025.